rs2070600 — AGER Gly82Ser

Missense variant in the AGER pattern-recognition receptor that reduces soluble RAGE shedding, amplifying inflammatory signaling via NF-κB and AGE pathway activation; associated with lung disease, diabetic complications, and modulated neuroinflammatory risk

See your personal result for AGER

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

AGER Gly82Ser — The Inflammation Receptor That Stays On

AGER encodes RAGE (Receptor for Advanced Glycation End-Products), a pattern recognition receptor11 pattern recognition receptor
A cell-surface protein that detects molecular signatures of tissue damage, pathogen invasion, or cellular stress — triggering immune responses in the immunoglobulin superfamily. RAGE is found on endothelial cells, neurons, immune cells, and lung epithelium. Its ligands include advanced glycation end-products22 advanced glycation end-products
Proteins and lipids that have been irreversibly modified by sugar molecules — they accumulate with diabetes, aging, and diets high in processed foods, HMGB1 (a nuclear protein released during cell injury), S100 proteins, and amyloid-beta. When ligands bind RAGE, the receptor activates NF-κB and MAPK cascades, driving sustained inflammatory gene expression.

The rs2070600 variant substitutes glycine for serine at position 82 in RAGE's ligand-binding V domain. This is one of the most functionally well-characterized common RAGE polymorphisms: the T (Ser82) allele has been consistently associated with substantially lower levels of soluble RAGE (sRAGE)33 soluble RAGE (sRAGE)
A truncated, secreted form of RAGE that acts as a decoy receptor — it binds and sequesters AGEs and other RAGE ligands in circulation, preventing them from activating cell-surface RAGE and dampening inflammatory signaling. Because sRAGE decoys circulating AGEs away from membrane-bound RAGE, lower sRAGE means more inflammatory signal reaches cells — a "gain of inflammation" effect.

The Mechanism

RAGE Gly82Ser is a missense change in the V-domain immunoglobulin fold44 immunoglobulin fold
The structural domain responsible for ligand binding in the RAGE extracellular region; substituting Ser for Gly at position 82 alters local conformation near the ligand-binding pocket that binds AGEs and HMGB1. The key functional consequence is impaired shedding of the soluble receptor form. When cells expressing the Ser82 variant are stimulated with HMGB1, they produce significantly less sRAGE than Gly82 cells (P=0.036), as demonstrated by Miller et al. (2016)55 Miller et al. (2016)
Miller S et al. The Ser82 RAGE variant affects lung function and serum RAGE in smokers and sRAGE production in vitro. Biochim Biophys Acta, 2016.

In a large community-based population study, Maruthur et al. (2015)66 Maruthur et al. (2015)
Maruthur NM et al. Genetics of plasma soluble receptor for advanced glycation end-products and cardiovascular outcomes. PLoS One, 2015 showed that the T allele was associated with approximately 50% lower sRAGE levels in 1,737 white participants (P=7.26×10⁻¹⁶) and similarly in 581 Black participants, with AGER variants explaining 21–26% of the entire variance in circulating sRAGE. The net effect: T allele carriers have less circulating decoy receptor and thus more unopposed membrane-bound RAGE activation when ligands are present.

AGE accumulation in tissues — driven by hyperglycemia, aging, and dietary AGE intake — is the primary driver of RAGE activation. RAGE in turn activates NF-κB, JAK/STAT, and MAPK signaling cascades, generating a self-amplifying inflammatory loop. In the brain, this AGE-RAGE-NF-κB axis disrupts the blood-brain barrier, activates microglia, and contributes to the neuroinflammatory milieu implicated in cognitive decline and neurodegeneration.

The Evidence

Lung disease. The most extensively studied phenotype is pulmonary, where RAGE plays a central role in alveolar homeostasis. In idiopathic pulmonary fibrosis (IPF), Yamaguchi et al. (2017)77 Yamaguchi et al. (2017)
Yamaguchi K et al. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis. Respirology, 2017 found that the rs2070600 minor allele was significantly more common in 87 IPF patients than in 303 controls (OR=1.84, 95% CI 1.08–3.10). Reduced sRAGE also predicted acute exacerbation and was an independent predictor of 5-year survival (HR=7.96). In combined pulmonary fibrosis and emphysema (CPFE), Kinjo et al. (2020)88 Kinjo et al. (2020)
Kinjo T et al. The Gly82Ser mutation in AGER contributes to pathogenesis of pulmonary fibrosis in CPFE in Japanese patients. Scientific Reports, 2020 found OR=1.93 (Pc=0.018) for CPFE vs. COPD in a dominant model (n=448 Japanese patients). Sin et al. (2022)99 Sin et al. (2022)
Sin S et al. Association between plasma sRAGE and emphysema according to the genotypes of AGER gene. BMC Pulmonary Medicine, 2022 demonstrated that in CC-genotype COPD patients (n=436), high sRAGE independently protected against emphysema (OR=0.24, 95% CI 0.11–0.51) — but this protective association was entirely absent in TC/TT carriers, whose RAGE shedding is blunted.

Diabetes and metabolic disease. A meta-analysis by Cheng et al. (2021)1010 Cheng et al. (2021)
Cheng Z et al. Ethnicity-dependent contribution of AGER gene in the pathogenesis of type 2 diabetes. Endocrine Journal, 2021 analyzed 29 studies (8,318 T2D cases, 5,589 controls) and found that in Caucasian populations rs2070600 conferred a 2.13-fold increased risk of type 2 diabetes (95% CI 1.28–3.55, I²=42.5%). In type 1 diabetes, Salonen et al. (2014)1111 Salonen et al. (2014)
Salonen KM et al. Associations of sRAGE concentrations with AGER gene polymorphisms in children with type 1 diabetes. Diabetes Care, 2014 found that the rs2070600 AA (CC in plus-strand) genotype associated with decreased sRAGE concentrations in 2,115 children, and lower sRAGE reflected more aggressive disease presentation.

Neuroinflammation and Alzheimer's risk. RAGE is the primary receptor for amyloid-beta aggregates, and its activation drives NF-κB-mediated neuroinflammation that accelerates Alzheimer's pathology. A study by Deo et al. (2020)1212 Deo et al. (2020)
Deo P et al. APOE ε4 carriers have a greater propensity to glycation and sRAGE which is further influenced by RAGE G82S polymorphism. J Gerontol, 2020 in 172 cognitively normal individuals showed that APOE ε4 carriers with the Ser82 variant had the most pronounced glycation burden and altered sRAGE dynamics — a combination that may amplify neuroinflammatory risk compared to either variant alone.

AGEs and sleep. A 2024 cross-sectional study in 1,732 Chinese adults Li et al. (2024)1313 Li et al. (2024)
Li L et al. Associations of advanced glycation end products with sleep disorders in Chinese adults. Nutrients, 2024 found that higher plasma AGE levels (CML, CEL, MG-H1) were independently associated with poor sleep quality (OR 1.33–1.61 per interquartile range), insomnia, short sleep duration, and excessive daytime sleepiness. Because the Ser82 variant reduces the circulating decoy that scavenges AGEs, carriers operating under higher AGE loads — from diet, diabetes, or aging — may experience greater RAGE-mediated signaling that contributes to sleep-disrupting neuroinflammation. Direct genetic studies of rs2070600 and sleep are lacking; this connection is mechanistically inferred.

Practical Actions

The central intervention for T allele carriers is reducing the AGE load that activates RAGE. Dietary AGEs — formed when food is cooked at high heat (grilling, frying, broiling) — are absorbed and accumulate in tissues. Switching to moist heat cooking methods reduces dietary AGE intake by 50–70% without restricting food choices. Controlling blood glucose is doubly important: hyperglycemia both accelerates endogenous AGE formation and activates RAGE, compounding the reduced sRAGE buffering capacity in T allele carriers. Monitoring fasting glucose and HbA1c is especially relevant given the meta-analytic evidence of elevated T2D risk.

sRAGE levels are also modifiable: aerobic physical activity raises circulating sRAGE (a genotype-independent effect that partially compensates for the genetic deficit), and caloric restriction reduces the AGE load that drives RAGE signaling.

Interactions

The rs2070600 T allele interacts with APOE ε4 status to amplify glycation burden and neuroinflammatory risk. Deo et al. (2020) showed that APOE ε4 carriers already exhibit elevated AGE formation; when the Ser82 RAGE variant reduces sRAGE-mediated AGE clearance, the combination creates an environment of heightened RAGE activation that may compound amyloid-beta toxicity in Alzheimer's pathology. This T allele × APOE ε4 interaction warrants a compound action for users carrying both risk variants (see interaction_candidates below).

The Ser82 variant also interacts with other AGER promoter polymorphisms (rs1800624, rs1800625) in determining the overall RAGE expression level. Haplotype analyses suggest the combined promoter + coding variants may have stronger effects than any single SNP alone.

Genotype Interpretations

What each possible genotype means for this variant.

CC Standard RAGE Signaling Normal

Normal RAGE receptor with typical sRAGE buffering capacity

With the CC genotype, glycine at position 82 in RAGE's V-domain maintains normal receptor conformation. When RAGE is activated by its ligands (AGEs, HMGB1, S100 proteins, amyloid-beta), the receptor sheds its extracellular domain as soluble RAGE (sRAGE) at normal rates. This sRAGE circulates as a decoy receptor — binding AGEs and HMGB1 before they reach membrane-bound RAGE — providing a self-regulating brake on RAGE-mediated inflammatory signaling.

In the Maruthur et al. (2015) community study, CC homozygotes maintained the highest sRAGE concentrations. In the Sin et al. (2022) COPD study, CC-genotype patients showed a significant protective association between sRAGE levels and emphysema severity (OR=0.24 per unit sRAGE), confirming that normal sRAGE production is functionally protective in pulmonary disease contexts.

CT Reduced sRAGE Buffering Intermediate

One Ser82 allele — moderately reduced sRAGE decoy capacity

With one Ser82 allele, approximately half of your RAGE receptors shed sRAGE at reduced rates when activated. The Maruthur et al. (2015) analysis showed a consistent gene-dose effect in both whites and Blacks: heterozygotes had intermediate sRAGE levels that tracked with allele count. AGER variants explained 21–26% of total circulating sRAGE variance, with rs2070600 being the dominant SNP.

The practical consequence depends on your AGE load. If your blood glucose is well controlled and dietary AGE intake is low, the reduced sRAGE buffering capacity has less impact. Under conditions of chronic hyperglycemia, aging-related AGE accumulation, or high dietary AGE exposure, the deficit in decoy receptor becomes more physiologically significant — more AGE-RAGE signaling reaches cells, driving NF-κB-mediated inflammatory gene expression.

The Cheng et al. (2021) meta-analysis found that rs2070600 T allele carriers had 2.13-fold elevated T2D risk in Caucasians; heterozygotes likely carry intermediate risk between CC and TT genotypes under the additive/codominant model.

TT Impaired sRAGE Buffering High Risk

Two Ser82 alleles — substantially reduced sRAGE decoy capacity and elevated inflammatory signaling

With two Ser82 alleles, both copies of your membrane RAGE shed sRAGE at reduced rates upon HMGB1 or AGE stimulation. The ~50% reduction in sRAGE documented by Maruthur et al. (2015) leaves circulating AGEs and HMGB1 less buffered, increasing their availability to bind and activate membrane-bound RAGE on endothelium, immune cells, neurons, and alveolar epithelium.

The lung phenotype is most clearly established. In COPD patients with CC genotype, high sRAGE independently protected against emphysema (OR=0.24). In TT carriers, this protective mechanism is lost — Sin et al. (2022) found no significant protective sRAGE-emphysema association in TC/TT genotypes (r=-0.017, P=0.836). IPF studies show OR=1.84 for minor allele carriers, and the Gly82Ser mutation was associated with OR=1.93 for progression to CPFE vs. COPD.

In the Alzheimer's context, the reduced sRAGE combined with APOE ε4 risk creates the highest-risk combination studied: Deo et al. (2020) showed Ser82 carriers have altered sRAGE dynamics that compound with APOE ε4-driven glycation burden. RAGE is the principal neuronal receptor for amyloid-beta, and its chronic activation drives the NF-κB-mediated neuroinflammation central to Alzheimer's pathology.

Plasma AGE levels are independently associated with poor sleep quality, insomnia, and excessive daytime sleepiness in population studies (ORs 1.33–1.61 per IQR increment). Because TT carriers have the most compromised AGE-clearing capacity, they operate at the highest RAGE activation state under conditions that elevate AGEs — aging, dietary exposure, and hyperglycemia — which may contribute to sleep-disrupting neuroinflammation.